Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: Systematic review and meta-analyses

BMJ (Online)

Volumn 352, Issue , 2016, Pages

  Brunström, Mattias ^a   Carlberg, Bo ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; PLACEBO;

ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; DIABETES MELLITUS; END STAGE RENAL DISEASE; HEART FAILURE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG EFFECTS; HYPERTENSION; MORTALITY; PATHOPHYSIOLOGY;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84960172050     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i717     Document Type: Article

References (80)

1. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 2009;27:923-34. doi:10.1097/HJH.0b013e32832aa6b5.
2. Mancia G. Effects of intensive blood pressure control in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 2010;122:847-9. doi:10.1161/CIRCULATIONAHA.110.960120.
3. Deedwania PC. Blood pressure control in diabetes mellitus: is lower always better, and how low should it goCirculation 2011;123:2776-8. doi:10.1161/CIRCULATIONAHA.111.033704.
4. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72. doi:10.1001/jama.289.19.2560.
5. Mancia G, De Backer G, Dominiczak A, et al. European Society of Hypertension European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension-The task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). Eur Heart J 2007;28:1462-536.
6. Buse JB, Ginsberg HN, Bakris GL, et al. American Heart Association American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007;115:114-26. doi:10.1161/CIRCULATIONAHA.106.179294.
7. Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-Analysis in 73,913 patients. J Hypertens 2011;29:1253-69. doi:10.1097/HJH.0b013e3283469976.
8. Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-Analyses of randomized trials. Circulation 2011;123:2799-810, 9, 810. doi:10.1161/CIRCULATIONAHA.110.016337.
9. Mancia G, Fagard R, Narkiewicz K, et al. American Heart Association American Diabetes Association. J Hypertens 2013;31:1281-357. doi:10.1097/01.hjh.0000431740.32696.cc.
10. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014;32:3-15. doi:10.1097/HJH.0000000000000065.
11. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507-20. doi:10.1001/jama.2013.284427.
12. American Diabetes Association. Standards of medical care in diabetes-2015: summary of revisions. Diabetes Care 2015;38:S4doi:10.2337/dc15-S003.
13. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-Analysis. JAMA 2015;313:603-15. doi:10.1001/jama.2014.18574.
14. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions.John Wiley & Sons Ltd, 2011.
15. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-Analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665. doi: 10.1136/bmj. b1665.
16. Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-Analysis. JAMA 2011;305:913-22. doi:10.1001/jama.2011.250.
17. Sipahi I, Swaminathan A, Natesan V, Debanne SM, Simon DI, Fang JC. Effect of antihypertensive therapy on incident stroke in cohorts with prehypertensive blood pressure levels: a meta-Analysis of randomized controlled trials. Stroke 2012;43:432-40. doi:10.1161/STROKEAHA.111.636829.
18. Higgins JPT, Altman DG, Gøtzsche PC, et al. Cochrane Bias Methods Group Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. doi:10.1136/bmj.d5928.
19. Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1?25 million people. Lancet 2014;383:1899-911. doi:10.1016/S0140-6736(14)60685-1.
20. Estacio RO, Coll Jr., Tran ZV, Schrier RW. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. Am J Hypertens 2006;19:1241-8. doi:10.1016/j.amjhyper.2006.05.011.
21. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23 (Suppl 2):B54-64.
22. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61:1086-97. doi:10.1046/j.1523-1755.2002.00213.x.
23. Cushman WC, Evans GW, Byington RP, et al. ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-85. doi:10.1056/NEJMoa1001286.
24. Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators. Effect of long-Acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004;364:849-57. doi:10.1016/S0140-6736(04)16980-8.
25. Wagener G. Calcium antagonists and hypertension: role of co-existent coronary disease, impaired renal function and diabetes. Erasmus University Rotterdam; 2007. http://hdl.handle.net/1765/10627.
26. Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-40. doi:10.1016/S0140-6736(07)61303-8.
27. de Galan BE, Perkovic V, Ninomiya T, et al. ADVANCE Collaborative Group. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009;20:883-92. doi:10.1681/ASN.2008070667.
28. Parving HH, Brenner BM, McMurray JJV, et al. ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204-13. doi:10.1056/NEJMoa1208799.
29. O'Hare P, Bilbous R, Mitchell T, O' Callaghan CJ, Viberti GC. Ace-Inhibitor Trial to Lower Albuminuria in Normotensive Insulin-Dependent Subjects Study Group. Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial. Diabetes Care 2000;23:1823-9. doi:10.2337/diacare.23.12.1823.
30. Ruggenenti P, Fassi A, Ilieva AP, et al. Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-51. doi:10.1056/NEJMoa042167.
31. Ruggenenti P, Fassi A, Ilieva A, et al. BENEDICT-B Study Investigators. Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. J Hypertens 2011;29:207-16. doi:10.1097/HJH.0b013e32834069bd.
32. Nissen SE, Tuzcu EM, Libby P, et al. CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004;292:2217-25. doi:10.1001/jama.292.18.2217.
33. Ruggenenti P, Lauria G, Iliev IP, et al. DEMAND Study Investigators. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension 2011;58:776-83. doi:10.1161/HYPERTENSIONAHA.111.174474.
34. Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Ménard J. DIABHYCAR Study Investigators. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004;328:495-9. doi:10.1136/bmj.37970.629537.0D.
35. Tillin T, Orchard T, Malm A, Fuller J, Chaturvedi N. The role of antihypertensive therapy in reducing vascular complications of type 2 diabetes. Findings from the DIabetic REtinopathy Candesartan Trials-Protect 2 study. J Hypertens 2011;29:1457-62. doi:10.1097/HJH.0b013e3283480db9.
36. Amery A, Birkenhäger W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High blood pressure in the Elderly trial. Lancet 1985;1:1349-54. doi:10.1016/S0140-6736(85)91783-0.
37. Zhang Y, Zhang X, Liu L, Zanchetti A, Grp FS. FEVER Study Group. Is a systolic blood pressure target 140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. Eur Heart J 2011;32:1500-8. doi:10.1093/eurheartj/ehr039
38. Fogari R, Preti P, Zoppi A, et al. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens 2002;15:1042-9. doi:10.1016/S0895-7061(02)03017-0.
39. Langford HG, Stamler J, Wassertheil-Smoller S, Prineas RJ. All-cause mortality in the Hypertension Detection and Follow-up Program: findings for the whole cohort and for persons with less severe hypertension, with and without other traits related to risk of mortality. Prog Cardiovasc Dis 1986;29(Suppl 1):29-54. doi:10.1016/0033-0620(86)90033-2.
40. Hansson L, Zanchetti A, Carruthers SG, et al. HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62. doi:10.1016/S0140-6736(98)04311-6.
41. Hypertension-Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA 1974;229:409-18. doi:10.1001/jama.1974.03230420021019.
42. Lewis EJ, Hunsicker LG, Clarke WR, et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60. doi:10.1056/NEJMoa011303.
43. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8. doi:10.1056/NEJMoa011489.
44. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 2008;31:2115-27. doi:10.1291/hypres.31.2115.
45. Laffel LMB, McGill JB, Gans DJ. North American Microalbuminuria Study Group. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med 1995;99:497-504. doi:10.1016/S0002-9343(99)80226-5.
46. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62. doi:10.1056/NEJM199311113292004.
47. Deedwania PC, Giles TD, Klibaner M, et al. MERIT-HF Study Group. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 2005;149:159-67. doi:10.1016/j.ahj.2004.05.056.
48. Gerstein HC, Yusuf S, Mann JFE, et al. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9. doi:10.1016/S0140-6736(99)12323-7.
49. Imai E, Chan JCN, Ito S, et al. ORIENT study investigators. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebocontrolled study. Diabetologia 2011;54:2978-86. doi:10.1007/s00125-011-2325-z.
50. Braunwald E, Domanski MJ, Fowler SE, et al. PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-68. doi:10.1056/NEJMoa042739.
51. Daly CA, Fox KM, Remme WJ, Bertrand ME, Ferrari R, Simoons ML. EUROPA Investigators. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 2005;26:1369-78. doi:10.1093/eurheartj/ehi225.
52. Lüders S, Schrader J, Berger J, et al. PHARAO Study Group. The PHARAO study: prevention of hypertension with the angiotensinconverting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 2008;26:1487-96. doi:10.1097/HJH.0b013e3282ff8864.
53. Yusuf S, Diener HC, Sacco RL, et al. PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008;359:1225-37. doi:10.1056/NEJMoa0804593.
54. Berthet K, Neal BC, Chalmers JP, et al. Perindopril Protection Against Recurrent Stroke Study Collaborative Group. Reductions in the risks of recurrent stroke in patients with and without diabetes: the PROGRESS Trial. Blood Press 2004;13:7-13. doi:10.1080/08037050410029605.
55. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009;361:40-51. doi:10.1056/NEJMoa0808400.
56. Brenner BM, Cooper ME, de Zeeuw D, et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9. doi:10.1056/NEJMoa011161.
57. Kowey PR, Dickson TZ, Zhang Z, Shahinfar S, Brenner BM, Investigators R. RENAAL Investigators. Losartan and end-organ protection-lessons from the RENAAL study. Clin Cardiol 2005;28:136-42. doi:10.1002/clc.4960280307.
58. Haller H, Ito S, Izzo JL Jr., et al. ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011;364:907-17. doi:10.1056/NEJMoa1007994.
59. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998;128:982-8. doi:10.7326/0003-4819-128-12-Part-1-199806150-00004.
60. Pfeffer MA, Braunwald E, Moyé LA, et al. The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-77. doi:10.1056/NEJM199209033271001.
61. Trenkwalder P, Elmfeldt D, Hofman A, et al. Study on COgnition and Prognosis in the Elderly (SCOPE). The Study on COgnition and Prognosis in the Elderly (SCOPE)-major CV events and stroke in subgroups of patients. Blood Press 2005;14:31-7. doi:10.1080/08037050510008823.
62. Curb JD, Pressel SL, Cutler JA, et al. Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996;276:1886-92. doi:10.1001/jama.1996.03540230036032.
63. Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry. Am J Cardiol 1996;77:1017-20. doi:10.1016/S0002-9149(97)89163-1.
64. Benavente OR, Coffey CS, Conwit R, et al. SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 2013;382:507-15. doi:10.1016/S0140-6736(13)60852-1.
65. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;338:1281-5. doi:10.1016/0140-6736(91)92589-T.
66. Staessen JA, Fagard R, Thijs L, et al. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-64. doi:10.1016/S0140-6736(97)05381-6.
67. Køber L, Torp-Pedersen C, Carlsen JE, et al. Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensinconverting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-6. doi:10.1056/NEJM199512213332503.
68. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13. doi:10.1136/bmj.317.7160.703.
69. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713-20. doi:10.1136/bmj.317.7160.713.
70. Fried LF, Emanuele N, Zhang JH, et al. VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369:1892-903. doi:10.1056/NEJMoa1303154.
71. Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75. doi:10.1056/NEJMoa010713.
72. Ogihara T, Saruta T, Rakugi H, et al. Valsartan in Elderly Isolated Systolic Hypertension Study Group. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension 2010;56:196-202. doi:10.1161/HYPERTENSIONAHA.109.146035.
73. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressurelowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs-overview and meta-Analyses. J Hypertens 2015;33:1321-41. doi:10.1097/HJH.0000000000000447.
74. Wright JT Jr., , Williamson JD, Whelton PK, et al. SPRINT Research Group. A randomized trial of intensive versus standard blood pressure control. N Engl J Med 2015;373:2103-16. doi:10.1056/NEJMoa1511939.
75. Sundström J, Sheikhi R, Ostgren CJ, et al. Blood pressure levels and risk of cardiovascular events and mortality in type-2 diabetes: cohort study of 34 009 primary care patients. J Hypertens 2013;31:1603-10. doi:10.1097/HJH.0b013e32836123aa.
76. Zhao W, Katzmarzyk PT, Horswell R, et al. Aggressive blood pressure control increases coronary heart disease risk among diabetic patients. Diabetes Care 2013;36:3287-96. doi:10.2337/dc13-0189.
77. Messerli FH, PanJr.ath GS. The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential?J Am Coll Cardiol 2009;54:1827-34. doi:10.1016/j. jacc.2009.05.073.
78. Rabkin SW, Waheed A, Poulter RS, Wood D. Myocardial perfusion pressure in patients with hypertension and coronary artery disease: implications for DBP targets in hypertension management. J Hypertens 2013;31:975-82. doi:10.1097/HJH.0b013e32835e831c.
79. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 2005;25:932-43. doi:10.1161/01.ATV.0000160548.78317.29.
80. Shu W, jing J, Fu LC, et al. The relationship between diastolic pressure and coronary collateral circulation in patients with stable angina pectoris and chronic total occlusion. Am J Hypertens 2013;26:630-5. doi:10.1093/ajh/hps096.